Imunon Inc IMNN

US Biotechnology

$1.59 ▼ -0.63% ($-0.01)

🎈 Low Float 📅 Earnings This Week

Open $1.58

Prev Close $1.60

Day Range $1.57 – $1.61

52W Range $1.47 – $8.19

Market Cap $6.68M

Beta 2.00

EPS (TTM) $-5.74

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1993-10-27
Shares Out.	4,200,000
Website	imunon.com/ ↗
Phone	18777348300
Employees	20
Net Income	-$4.2M
Free Cash Flow	-$15.1M
Total Assets	$8.0M
Total Liabilities	$4.7M
Equity	$3.4M

About Imunon Inc

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Imunon Inc is a publicly traded company under the ticker symbol IMNN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.